Currently, a phase II/III clinical trial (SNIFF: Study of Nasal Insulin to Fight Forgetfulness) is underway in amnestic MCI and mild AD patients to find out the outcome of intranasal insulin on changes in CSF biomarkers, cognitive decline, and brain volume loss (NCT01767909). The gene discussed is INS; the disease is Mental deterioration.